| Name | Title | Contact Details |
|---|
Innoviva is a healthcare royalty and asset management company that focuses on maximizing the long-term potential of its royalty portfolio and fueling innovation in areas of significant, often overlooked unmet medical need.
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
Kyn Therapeutics is building a new generation of immuno-oncology therapies targeting powerful immunosuppressive metabolic networks. We envision a future where immunotherapies are the foundation of every cancer patient`s treatment, delivering rapid and durable responses. The Kyn team is composed of drug hunters, translational researchers and entrepreneurs drawn from many of the largest innovators in biotechnology supported by world-class advisors, and is backed by a seasoned board of directors anchored by OrbiMed Healthcare Fund Management and Atlas Venture. Kyn Therapeutics is headquartered in the biotech hub of Cambridge, Massachusetts.
Centerfirst was founded in early 2004 to help healthcare leaders maximize the value of their call centers.
TEK Solutions Inc is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.